levels in health information technology (IT) that would make health care delivery more efficient and eventually could lead to lower spending and improved health outcomes. 3 Other papers have compared health outcomes. 4 Our previous work has consistently shown that the United States has lower utilization rates than most other OECD countries (for example, numbers of hospital days and physician visits per capita). In addition, the supply of many medical services (hospital beds per capita) and expensive technologies such as magnetic resonance imaging (MRI) units and computed tomography (CT) scanners is lower in the United States than in many other OECD countries (Exhibit 2). 5 In each of these papers, we have returned to the conclusion that much of the spending differences are attributable to the higher per capita income of the United States and the fact that Americans pay much higher prices for medical care services ("It's the Prices, Stupid"). 6 In this paper we return to an issue that we examined several years ago: the re-H e a l t h S p e n d i n g turn on investment in health care. We begin with a crude measure of outcomeslife expectancy-to examine which countries have better-than-expected longevity, given their level of health care spending and controlling for their per capita income. We then take a closer look at how the United States compares to other OECD countries on sixteen different process and outcome measures collected by the OECD.
Health Spending Growth In 2005
The Congressional Budget Office (CBO), Federal Reserve Bank, and other government agencies are forecasting that the percentage of GDP spent on health in the United States will continue to increase, and some policymakers are forecasting serious economic implications if this percentage exceeds certain thresholds. 7 One concern is that all of the real growth in the economy will be devoted to health care once the percentage of GDP spent on health exceeds a certain threshold. Denmark actually spent a greater percentage of its GDP on health care in 1970 than the United States (7.9 percent versus 7.0 percent) but now spends only 9.1 percent. In 2005, the median OECD country spent 9.1 percent of its GDP on health care, and only seven other countries spent more than 10 percent (Exhibit 2). 9 This raises the concern over opportunity costs: as more resources are devoted to health care, fewer resources are left to be spent on other goods and services.
Public, Private, And Out-Of-Pocket Revenues
In most OECD countries, more than 75 percent of health revenues were from public sources in 2005 (Exhibit 1). 10 Only the United States, Mexico, and Greece had less than half of their revenues coming from public sources. However, in absolute-dollar terms, a different picture emerges. Adjusting for purchasing power parity (PPP), the United States spent $2,884 from public sources. Only Luxembourg and Norway spent more public dollars per capita than the United States, and these countries were able to cover their entire populations using public funds. Out-of-pocket spending is often identified as a way to reduce moral hazard. 12 It is also a measure of underinsurance. Out-of-pocket spending in the United States was about twice the OECD median in 2005. Switzerland had the highest out-ofpocket spending per capita ($1,276), with the United States second ($842).
Value Per Dollar Spent
A number of recent studies have compared health care quality, on both process and outcome measures, in the United States with that of other countries. 13 One question these studies are trying to answer is whether the United States is obtaining value for its higher level of health spending. Their consistent finding is that despite the higher spending, the United States scored average or slightly worse than average on many quality-of-care indicators compared to other industrialized countries. Perhaps even more troubling is that improvements in health status are occurring at a lower rate than in most other OECD countries. 14 We chose one commonly used indicator of health care quality-life expectancy-and attempted to see which countries were receiving the greatest value per dollar spent. We plotted the difference between the actual average life expectancy in a country and the predicted average life expectancy based on a bivariate regression of life expectancy and GDP per capita (measured in PPP; Exhibit 3). 15 For example, actual U.S. life expectancy for 2005 was 77.8 years, and predicted life expectancy based solely on the U.S. per capita income was 80.9 years. The difference in the two numbers (3.1 years) is plotted in Exhibit 3. On the horizontal axis, we plotted the difference between actual average health care spending per capita and predicted spending based on a similar bivariate regression of per capita spending on per capita GDP, adjusted for differences in cost of living. 16 For example, actual U.S. per capita health spending was $6,401, and predicted health spending based solely on per capita income was $4,204 in 2005.
Exhibit 3 shows four quadrants. 17 The upper-left-hand quadrant is where the country spent less than predicted on health care and yet had better-thanexpected length of life. Japan, the country with the highest life expectancy among all OECD countries, had the largest gap between actual and expected life-years (3.5). Spain and Italy also had better-than-expected life expectancy and lowerthan-expected per capita spending. The lower-right-hand quadrant is where a country spends more than expected on health care yet has worse-than-expected 
D a t a W a t c h "Out-of-pocket spending in the United States was about twice the OECD median in 2005."
life expectancy. The United States is a clear outlier, with the largest spending gap of any country and the largest differences in life expectancy. Only Turkey and Belgium joined the United States in the lower-right-hand quadrant. 18 The relationship between life expectancy and health spending is admittedly a crude analysis of value per health care dollar. 19 Many other factors influence life expectancy, and life expectancy is only one measure of health status. An extensive literature has further explored other determinants of life expectancy. For example, Ellen Nolte and Martin McKee showed that the United States had the most lives (75,000-101,000 fewer deaths per year) to gain compared to eighteen other industrialized countries by treating preventable diseases with "timely and efficient health care." 20 A study by Ken Thorpe and colleagues concluded that the United States could reduce health spending by reducing "treated prevalence" rates-the product of the prevalence rate of chronic diseases and medication use for conditions-for which the United States is significantly higher compared to European countries. 21 Other nonmedical factors (such as social solidarity, income distribu- tion, and job loss) also could affect life expectancy and the value of health spending. Other analyses have examined whether the type of health system influences health outcomes. For example, Eddy van Doorslaer and colleagues found no significant differences between health systems and equity (an alternative quality measure) in the delivery of health care, although the United States and United Kingdom were notable outliers. 22 
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Quality Comparisons
In 2001 the OECD began a process to collect comparable data on risk, process, and outcome indicators for as many of the thirty OECD countries as possible. 23 The methodology was loosely based on the methodology created in a five-country comparison of outcomes. 24 The most recent list includes nineteen measures for which comparable data were available for measures chosen for their impact on health status, policy importance, how likely they are to be influenced by the health care system, face and content validity, and reliability. 25 In spite of considerable work by analysts from the various countries, the indicators remain a convenience sample, and many areas in medical care are not represented.
The United States submitted data on all but three indicators, and more are in progress with the cooperation of the Agency for Healthcare Research and Quality (AHRQ) Prevention Quality Indicator project. 26 Although the results are dependent on the number of countries reporting and which countries report, the results suggest the United States is not receiving good value for a country that spends more than any other OECD country (Exhibit 4). Overall, the United States is about as likely to be in the top half as in the bottom half of the countries submitting data.
For some indicators the United States ranked at or near the top. For example, it ranked highest on cervical cancer screening and second on relative survival rates for breast and colorectal cancer. For some vaccination measures the United States scored high (lowest incidence of measles), but on other measures it did relatively poorly (pertussis vaccinations for two-year-old children). On the two avoidable risk measures, the United States ranked high on one indicator (the second-lowest percentage of smokers among the total population) but had one of the highest asthma admission rates per 100,000 discharges. 27 The latter is deemed a sign of lack of access to appropriate medical care, because hospitalization resulting from asthma is considered to be avoidable with appropriate medical care.
Conclusion
In 2005 the United States continued to spend much more on health care than any other OECD country. In spite of myriad cost containment initiatives during the past thirty-five years, the annual rate of increase in real U.S. health care spending is slightly above the average annual rate of increase in the median OECD country. And the United States experienced the largest increase in the percentage of its GDP dedicated to health care among all OECD countries during 1970-2005. What does the country have to show for this higher level of spending? U.S. life expectancy is lower than would be predicted based on U.S. per capita income. The United States is just as likely to be in the bottom or top half on a series of health indicators. The value per dollar for health care in the United States is further complicated by limitations in access to care; the country is not able to provide univer-H e a l t h S p e n d i n g 
